Eupraxia Pharmaceuticals (EPRX) Stock Chart & Stock Price History $3.49 +0.12 (+3.56%) (As of 11/22/2024 ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Eupraxia Pharmaceuticals Stock Price Performance 5 Day Performance+11.86%1 Month Performance+39.60%3 Month Performance+30.71%6 Month Performance+22.46% Receive EPRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address “Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. EPRX Stock Chart for Saturday, November, 23, 2024 EPRX Chart by TradingView Eupraxia Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/22/2024$3.37$3.49+3.56%$3.49$3.2726,384 shs$95.21 million11/21/2024$3.62$3.37-6.91%$3.69$3.2734,485 shs$91.93 million11/20/2024$3.26$3.62+11.04%$4.08$3.41238,253 shs$98.75 million11/19/2024$3.12$3.26+4.49%$3.26$3.0514,598 shs$88.93 million11/18/2024$3.13$3.12-0.34%$3.14$3.106,492 shs$85.11 million11/15/2024$2.90$3.13+7.96%$3.14$2.8015,382 shs$85.41 million Get the Latest News and Ratings for EPRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/14/2024$2.84$2.90+2.11%$3.14$2.909,957 shs$79.11 million11/13/2024$2.90$2.84-2.07%$2.99$2.7815,387 shs$77.48 million11/12/2024$3.01$2.90-3.65%$2.93$2.822,223 shs$79.11 million11/11/2024$3.21$3.01-6.37%$3.35$3.015,613 shs$82.11 million11/08/2024$3.16$3.21+1.73%$3.29$3.122,609 shs$87.70 million11/07/2024$3.11$3.16+1.65%$3.41$3.1011,411 shs$86.21 million11/06/2024$3.29$3.11-5.51%$3.19$3.087,303 shs$84.81 million11/05/2024$3.48$3.29-5.46%$3.39$3.0115,054 shs$89.75 million11/04/2024$3.10$3.48+12.26%$3.49$2.9551,007 shs$94.93 million11/01/2024$2.50$3.07+22.80%$3.79$2.50210,517 shs$83.75 million10/31/2024$2.50$2.50$2.50$2.472,149 shs$68.21 million10/30/2024$2.43$2.50+2.88%$2.50$2.472,149 shs$68.21 million10/29/2024$2.55$2.43-4.71%$2.80$2.4110,214 shs$66.30 million10/28/2024$2.58$2.55-1.16%$2.56$2.453,988 shs$69.56 million10/25/2024$2.49$2.58+3.61%$2.58$2.334,566 shs$70.39 million10/24/2024$2.50$2.49-0.40%$2.49$2.37788 shs$67.93 million10/23/2024$2.41$2.50+3.73%$2.50$2.451,730 shs$68.21 million10/22/2024$2.43$2.41-0.82%$2.51$2.316,828 shs$65.75 million Related Companies Ginkgo Bioworks Stock Chart Valneva Stock Chart Amylyx Pharmaceuticals Stock Chart Kamada Stock Chart biote Stock Chart Q32 Bio Stock Chart Jasper Therapeutics Stock Chart AC Immune Stock Chart Cryoport Stock Chart Design Therapeutics Stock Chart Receive EPRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:EPRX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.